Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

8DCY

CCHFV GP38 Hoti/Kosovo bound with 13G8 Fab

Summary for 8DCY
Entry DOI10.2210/pdb8dcy/pdb
Descriptor13G8 Heavy Chain, 13G8 Light Chain, Envelopment polyprotein, ... (5 entities in total)
Functional Keywordscrimean-congo hemorrhagic fever, cchfv, glycoprotein, gp38, hoti, kosovo, 13g8, fab, viral protein
Biological sourceMus musculus
More
Total number of polymer chains3
Total formula weight80263.45
Authors
Durie, I.A.,Bergeron, E.,Pegan, S.D.,McGuire, J. (deposition date: 2022-06-17, release date: 2022-12-07, Last modification date: 2024-10-09)
Primary citationDurie, I.A.,Tehrani, Z.R.,Karaaslan, E.,Sorvillo, T.E.,McGuire, J.,Golden, J.W.,Welch, S.R.,Kainulainen, M.H.,Harmon, J.R.,Mousa, J.J.,Gonzalez, D.,Enos, S.,Koksal, I.,Yilmaz, G.,Karakoc, H.N.,Hamidi, S.,Albay, C.,Spengler, J.R.,Spiropoulou, C.F.,Garrison, A.R.,Sajadi, M.M.,Bergeron, E.,Pegan, S.D.
Structural characterization of protective non-neutralizing antibodies targeting Crimean-Congo hemorrhagic fever virus.
Nat Commun, 13:7298-7298, 2022
Cited by
PubMed Abstract: Crimean-Congo Hemorrhagic Fever Virus (CCHFV) causes a life-threatening disease with up to a 40% mortality rate. With no approved medical countermeasures, CCHFV is considered a public health priority agent. The non-neutralizing mouse monoclonal antibody (mAb) 13G8 targets CCHFV glycoprotein GP38 and protects mice from lethal CCHFV challenge when administered prophylactically or therapeutically. Here, we reveal the structures of GP38 bound with a human chimeric 13G8 mAb and a newly isolated CC5-17 mAb from a human survivor. These mAbs bind overlapping epitopes with a shifted angle. The broad-spectrum potential of c13G8 and CC5-17 and the practicality of using them against Aigai virus, a closely related nairovirus were examined. Binding studies demonstrate that the presence of non-conserved amino acids in Aigai virus corresponding region prevent CCHFV mAbs from binding Aigai virus GP38. This information, coupled with in vivo efficacy, paves the way for future mAb therapeutics effective against a wide swath of CCHFV strains.
PubMed: 36435827
DOI: 10.1038/s41467-022-34923-0
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (3.62 Å)
Structure validation

227561

PDB entries from 2024-11-20

PDB statisticsPDBj update infoContact PDBjnumon